Anavex Strongly focused
  on increasing value
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT

Stock Quote
Share Information
Press Releases
SEC Filings
Analyst Coverage
Code of Conduct
Investor Kit
Biopharma Industry
Media
 
Media

Business and Industry Press

May 5, 2014
Spotlight on Bio Advances
Success Stories: Trending toward multiple pathways
 Click here to read article

March 27, 2014
Journal of International Pharmaceutical Industry
The Anticipated Clinical Effect of the new Alzheimer Drug ANAVEX PLUS in a Predictive Humanised Cortical Cognitive Model for Alzheimer's Disease
 Click here to read article

February 4, 2014
SNNLive
SNNLive spoke with Christopher Missling, PhD, President and CEO of Anavex Life Sciences Corp. (OTCQB: AVXL) at Biotech Week 2014 in San Francisco, CA.
 Click here to watch interview

January 26, 2014
Alzheimer's & Dementia Weekly
“Anavex Plus” May Double Aricept's Memory Boost
 Click here to read article

December 17, 2013
BioTuesdays
Anavex readies trial of AZ combo drug
 Click here to read article

November 13, 2013
Drug Discovery and Development
SFN2013: Anavex Announces Positive Data for Alzheimer’s Drug
 Click here to read article

November 12, 2013
StockNewsNow Radio
Host Gary McKenzie speaks with Dr. Christopher U. Missling, President and CEO, Anavex Life Sciences Corp.
 Click here to listen to interview

November 6, 2013
Medical News Today
Anavex 2-73 blocks Tau and amyloid-beta proteins in a preclinical model of Alzheimer’s disease
 Click here to read article

November 6, 2013
Medical Laboratory Observer
Investigational drug blocks tau and amyloid-beta proteins in a preclinical model of Alzheimer’s disease
 Click here to read article

November 4, 2013
BioTuesdays
Anavex’s Alzheimer’s disease data published
 Click here to read article

October 24, 2013
Dementia Today
Anavex Encouraged by New Study that May Explain Efficacy of ANAVEX 2-73 for Alzheimer’s Disease
 Click here to read article

July 8, 2013
New York Citybiz List
Anavex Raises $2.6 Million, Appoints Christopher U. Missling CEO
 Click here to read article

March 18, 2013
Foundation for Mitochondrial Medicine
ANAVEX 2-73 linking mitochondrial functionality to Alzheimer’s
 Click here to read article

July 17, 2011
The Wall Street Journal
Alzheimer’s Treatment Showcase Is Set
 Click here to read article

July 15, 2011
BioMedReports.com
News Makers: Also Friday... News in the healthcare sector on July 15, 2011.
 Click here to read article

July 7, 2011
Pharmaceutical Business Review
Clinical Trials News: Anavex starts 30mg dose step in Alzheimer’s drug Phase 1 trial
 Click here to read article

July 6, 2011
Benzinga.com
Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well
 Click here to read article

July 6, 2011
BioMedReports.com
News Makers: Anavex Starts Phase I Clinical Trial To Evaluate ANAVEX 2-73
 Click here to read article

May 2, 2011
Pharmaceutical Business Review
First-In-Human Dosing Commenced in Alzheimer’s Trial
 Click here to read article

April 1, 2011
Pharmaceutical Business Review
Clinical Trials News: Anavex screens first subject in Alzheimer’s drug trial
 Click here to read article

March 21, 2011
Drug Discovery & Development
Anavex Granted Alzheimer’s Trial Approval
 Click here to read article

March 16, 2011
International Business Times
Germans to Receive First Dose of Anavex Life Sciences’ (AVXL) Alzheimer Drug
 Click here to read article

March 10, 2011, page 14
Pharmaceutical Executive Global Digest
Appointments: Dr. Paul Aisen
 Click here to read article

January 2, 2011
About.com Biotech/Biomedical Blog
Theresa’s Biotech/Biomedical Blog: Top Small Biotech Companies of 2010
 Click here to read article

December 26, 2010 - January 2, 2011
Alzheimer’s Weekly
2010 Trial-of-the-Year: Anavex Enters Phase I
 Click here to read article

September 14, 2010
Pharmaceutical Business Review
Anavex Life Sciences publishes ANAVEX 2-73 data
 Click here to read article

July/August 2010, page 18
PharmaVOICE Magazine
The PharmaVOICE 100
Dr. Cameron Durrant: Grounded in Excellence
 Click here to read article

March 31, 2010
Applied Clinical Trials Blog
Chasing After Amyloid
 Click here to read article


Radio Interview


March 26, 2010
Business @ Night on CFRA AM News Talk Radio (Ottawa, Ontario)
In a two-part interview, Business @ Night Host Greg Hebert speaks with Dr. Cameron Durrant, Executive Chairman of Anavex Life Sciences, about the company’s upcoming clinical trials and its compelling drug candidate for the treatment and modification of Alzheimer’s disease.

Listen to:
 Part 1 of Dr. Durrant’s interview (click here)
 Part 2 of Dr. Durrant’s interview (click here)

© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.